← All companies

LEXX

Lexaria Bioscience Corp.

LEXX Nasdaq Pharmaceutical Preparations EDGAR ↗

$5.62

+0.87 +18.32%

Key statistics

from XBRL data in SEC filings

Market cap

$139M

Revenue (TTM)

$194K

Net income (TTM)

-$7.73M

EPS (TTM)

$-0.35

P/E ratio

—

Dividend yield

—

Free cash flow

-$10.5M

Cash

$3.50M

Total assets

$4.78M

Gross margin

100.0%

52-week range

$4.62 – $23.25

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Modified rights of security holders; Amended charter or bylaws Jul 30, 2026 10-Q Quarter ended 2026-05-31 Jul 13, 2026 10-Q Quarter ended 2026-02-28 Apr 13, 2026 8-K Delisting notice or listing-rule failure Feb 6, 2026 8-K Shareholder vote results Jan 28, 2026 10-Q Quarter ended 2025-11-30 Jan 13, 2026 8-K Entered a material agreement; Unregistered sale of equity; Other events Dec 16, 2025 10-K Fiscal year ended 2025-08-31 Nov 28, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Sep 29, 2025 8-K Terminated a material agreement Sep 25, 2025 10-Q Quarter ended 2025-05-31 Jul 14, 2025 8-K Entered a material agreement Jun 12, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Apr 28, 2025 10-Q Quarter ended 2025-02-28 Apr 14, 2025 8-K Entered a material agreement Feb 5, 2025 8-K Shareholder vote results Jan 15, 2025 10-Q Quarter ended 2024-11-30 Jan 10, 2025 8-K Director or officer change Jan 3, 2025 8-K Entered a material agreement Dec 18, 2024 10-K Fiscal year ended 2024-08-31 Nov 26, 2024 8-K Item 5.08 Oct 18, 2024 8-K Entered a material agreement; Unregistered sale of equity; Other events Oct 16, 2024 8-K Director or officer change Oct 2, 2024 8-K Director or officer change; Regulation FD disclosure Sep 5, 2024 8-K Entered a material agreement Aug 22, 2024 8-K Director or officer change; Regulation FD disclosure Jul 17, 2024 10-Q Quarter ended 2024-05-31 Jul 12, 2024 8-K Entered a material agreement; Unregistered sale of equity Apr 30, 2024 8-K Shareholder vote results Apr 24, 2024 10-Q Quarter ended 2024-02-29 Apr 9, 2024 8-K Entered a material agreement Mar 21, 2024 8-K Director or officer change Mar 15, 2024 8-K Other events Mar 1, 2024 8-K Entered a material agreement; Unregistered sale of equity; Other events Feb 16, 2024 8-K Other events Jan 30, 2024 8-K Regulation FD disclosure Jan 24, 2024 10-Q Quarter ended 2023-11-30 Jan 12, 2024 8-K Regulation FD disclosure Jan 4, 2024 10-K Fiscal year ended 2023-08-31 Nov 20, 2023 8-K Other events Nov 3, 2023